Skip to content
value.today

Cyclacel Pharmaceuticals, Inc.

Formerly Molecurx, Inc., CDR Therapeutics, Inc., Xcyte Therapeutics, Inc.

Total raised
$15 M
1 round on record
Latest round
$15 M
Oct 2010
First round on record
Oct 2010
Today
Went public
See the company page

Cyclacel Pharmaceuticals, Inc. is listed today as Bio Green Med Solution, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cyclacel Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2025$1 MPrivate placement after listingUnder $2 million

Cyclacel Pharmaceuticals, Inc.: Private sale, Mar 2025

Investors in this round

4 investors had bought by the notice of Mar 25, 2025: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Datuk Dr. Doris Wong Sing Ee · Executive Officer · The Chief Executive Officer
  • Kiu Cu Seng · Executive Officer · The Chief Financial Officer
  • Avraham Fock Ben-Tzvi · Director
  • David Fock Natan · Director
  • Kwang Fock Chong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Company sold $1,000,000 of convertible Series E Preferred Stock”

Signed by Datuk Dr.Doris Wong Sing Ee, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 25, 2025. Read the notice at the SEC.

equitySEC
Nov 2024$2 MPrivate placement after listing$2 to $10 million

Cyclacel Pharmaceuticals, Inc.: Private sale, Nov 2024

Investors in this round

1 investor had bought by the notice of Nov 26, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$189,969
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul McBarron · Executive Officer, Director
  • Spiro Rombotis · Executive Officer, Director
  • Brian Schwartz · Director
  • Christopher Henney · Director
  • Karin Walker · Director
  • Kenneth Ferguson · Director
  • Robert Spiegel · Director
  • Samuel Barker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. (CRD 000000375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “The Company (a) paid Wainwright an aggregate cash fee of 7% of the gross proceeds, a management fee of 1% of the gross proceeds, expense reimbursement of $25,000 and (b) issued them warrants to purchase up to 298,137 shares.”

Signed by Paul McBarron, Executive Vice President-Finance, CFO and COO. Source: SEC Form D, newest notice filed Nov 26, 2024. Read the notice at the SEC.

equity, optionsSEC
May 2024$8 MPrivate placement after listing$2 to $10 million

Cyclacel Pharmaceuticals, Inc.: Private sale, May 2024

Investors in this round

1 investor had bought by the notice of May 17, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$640,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul McBarron · Executive Officer, Director
  • Spiro Rombotis · Executive Officer, Director
  • Brian Schwartz · Director
  • Christopher Henney · Director
  • Karin Walker · Director
  • Kenneth Ferguson · Director
  • Robert Spiegel · Director
  • Samuel Barker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. (CRD 000000375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “In connection with the private placement, the placement agent received $640,000 in cash and warrants to purchase up to 298,137 shares of Common Stock exercisable at $2.0125 per share, among other items.”

Signed by Paul McBarron, Executive Vice President-Finance, CFO and COO. Source: SEC Form D, newest notice filed May 17, 2024. Read the notice at the SEC.

equity, optionsSEC
Dec 2020$7 MPrivate placement after listing$2 to $10 million

Cyclacel Pharmaceuticals, Inc.: Private sale, Dec 2020

Investors in this round

1 investor had bought by the notice of Jan 4, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark H. Kirschbaum · Executive Officer
  • Paul McBarron · Executive Officer, Director
  • Spiro Rombotis · Executive Officer, Director
  • Brian L. Schwartz · Director
  • Christopher S. Henney · Director
  • Gregory T. Hradsky · Director
  • Karin L. Walker · Director
  • Lloyd T. Sems · Director
  • Robert J. Speigel · Director
  • Samuel L. Barker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul McBarron, Executive Vice President-Finance, CFO and COO. Source: SEC Form D, newest notice filed Jan 4, 2021. Read the notice at the SEC.

equity, optionsSEC
Mar 2012$3 MPrivate placement after listing$2 to $10 million

Cyclacel Pharmaceuticals, Inc.: Private sale, Mar 2012

Investors in this round

7 investors had bought by the notice of May 1, 2012: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Judy Chiao · Executive Officer
  • Paul McBarron · Executive Officer, Director
  • Spiro Rombotis · Executive Officer, Director
  • Christopher S. Henney · Director
  • Daniel K. Spiegelman · Director
  • David K. U'Prichard · Director
  • Gregory K. Hradsky · Director
  • John S. Banham · Director
  • Lloyd K. Sems · Director
  • Nicholas S. Bacopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul McBarron, CFO, COO and EVP-Finance. Source: SEC Form D, newest notice filed May 1, 2012. Read the notice at the SEC.

equity, optionsSEC
Oct 2010$15 MNo. 1$10 to $50 million

Cyclacel Pharmaceuticals, Inc.: Raise no. 1, Oct 2010

Investors in this round

20 investors had bought by the notice of Oct 21, 2010: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $22 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$988,015
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul McBarron · Executive Officer, Director
  • Spiro Rombotis · Executive Officer, Director
  • Christopher Henney · Director
  • Daniel K. Spiegelman · Director
  • David K. U'Prichard · Director
  • John Banham · Director
  • Nicholas Bacopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners LLC (CRD 15407) · Newport Beach, CaliforniaSold in CA, NY
  • Lazard Capital Markets LLC (CRD 134736) · New York, New YorkSold in CA, NY

Remarks in the notice

  • On fees: “The Company has paid an aggregate of $988,014.67 in sales commissions. Up to an additional $451,741.14 will be paid, assuming all of the options are exercised in full.”

Signed by Spiro Rombotis, President and CEO. Source: SEC Form D, newest notice filed Oct 21, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Bio Green Med Solution, Inc., its revenue in fiscal 2025 came from these product and service lines: Product Revenue Fire Safety $750,000 (100%), Fire Safety Equipment $600,000 (81%), Safety Aparel $120,000 (16%), Project Supply and Installation $20,000 (3%), Maintenance and Servicing $10,000 (1%).

    Annual report (SEC XBRL) · Dec 2025

  • Cyclacel Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2025).

    SEC Form D · Mar 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2025

Products and services#

No products or services of Cyclacel Pharmaceuticals, Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Cyclacel Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
David E. LazarPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2025)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 20 investors.

Largest shareholders today

Institutions holding Bio Green Med Solution, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cyclacel Pharmaceuticals, Inc.
NameRoleNamed in
Datuk Dr. Doris Wong Sing EeThe Chief Executive OfficerMar 2025
Kiu Cu SengThe Chief Financial OfficerMar 2025
Paul McBarronExecutive officerNov 2024
Spiro RombotisExecutive officerNov 2024
Mark H. KirschbaumExecutive officerJan 2021
Judy ChiaoExecutive officerMay 2012
Avraham Fock Ben-TzviDirectorMar 2025
David Fock NatanDirectorMar 2025
Kwang Fock ChongDirectorMar 2025
Brian SchwartzDirectorNov 2024
Christopher HenneyDirectorNov 2024
Karin WalkerDirectorNov 2024
Kenneth FergusonDirectorNov 2024
Paul McBarronDirectorNov 2024
Robert SpiegelDirectorNov 2024
Samuel BarkerDirectorNov 2024
Spiro RombotisDirectorNov 2024
Brian L. SchwartzDirectorJan 2021
Christopher S. HenneyDirectorJan 2021
Gregory T. HradskyDirectorJan 2021
Karin L. WalkerDirectorJan 2021
Lloyd T. SemsDirectorJan 2021
Robert J. SpeigelDirectorJan 2021
Samuel L. BarkerDirectorJan 2021
Daniel K. SpiegelmanDirectorMay 2012
David K. U'PrichardDirectorMay 2012
Gregory K. HradskyDirectorMay 2012
John S. BanhamDirectorMay 2012
Lloyd K. SemsDirectorMay 2012
Nicholas S. BacopoulosDirectorMay 2012
John BanhamDirectorOct 2010
Nicholas BacopoulosDirectorOct 2010

About

Company in Berkeley Heights, United States.

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.